Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension (Q46431027)

22 December 2017

title

Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension (English)

1 reference

22 December 2017

author

Dimitri P Mikhailidis

2

object named as

Dimitri P Mikhailidis

1 reference

ORCID Public Data File 2021

22 December 2017

1 reference

author name string

John A Papadakis

1

1 reference

22 December 2017

George E Vrentzos

3

1 reference

22 December 2017

Antonia Kalikaki

4

1 reference

22 December 2017

Irene Kazakou

5

1 reference

22 December 2017

Emmanuel S Ganotakis

6

1 reference

22 December 2017

publication date

1 April 2005

1 reference

22 December 2017

Clinical and Applied Thrombosis-Hemostasis

published in

1 reference

22 December 2017

volume

11

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

139-146

1 reference

22 December 2017

A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effects of antihypertensive therapy on haemostatic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The effect of fluvastatin on plasma fibrinogen levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Stroke: epidemiology, clinical picture, and risk factors--Part I of III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Epidemiology of fibrinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Valsartan improves fibrinolytic balance in atherosclerotic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Clinical and rheological effects of nifedipine in Raynaud's phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Celiprolol in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Impact of lipid and ACE inhibitor therapy on cardiovascular disease and metabolic abnormalities in the diabetic and hypertensive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The association between antihypertensive drug therapies and plasma lipid levels in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107602960501100203

10.1177/107602960501100203

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

15821820

1 reference

22 December 2017